-
I started covering Cytori back in 2007 and if you do a search you can find plenty here at the Medical Quack to include the initial use in Europe and the fact that GE decided to invest and help commercialize. The system takes a women’s own fat cells and basically recycles them for breast restoration...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Mar 2 2011
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Cancer, clinical trials, GE, Stem Cells, Regenerative Medicine, heart attacks, Cytori, breast reconstruction, fat cells
-
As you can see from the image below the company has a melanoma drug about ready to submit for on approval and they are working with Roche (Genentech) for the marketing. The skin cancer drug helps sustain life and is an oral medication taken. Daiichi Sankyo is located in Japan and for the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Mar 1 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Biotech, Cancer, FDA, Oncology, Doctors, Japan, melanoma, Mergers and Acquisitions, Daiichi Sankyo, Plexxikon
-
The date for the hearing is a few months off and until that time the drug is still approved as a first line treatment of the HER2 Negative mBC (breast cancer). Genentech filed the request for a formal hearing and the opportunity to present additional documentation to support continued use for treating...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Feb 25 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, health insurance, Claims, Cancer, Oncology, Breast Cancer, Roche, healthcare reform, Susan G. Komen, Avastic, FDA. Genentech
-
By now most of us know about the daVinci robot that is used for prostate surgeries and this new study suggests that it may not be advisable for every smaller community hospital to perform the procedure but rather rely on the high volume centers of excellence where surgeons are fully trained and familiar...
-
We normally think about sequencing our entire genome and with this study the genome of the tumor was used to compare against white blood cells from the patient. When you stop and think of all the data that has to be sifted through, it’s a lot. The Broad Institute, Dana-Farber Cancer Institute...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Thu, Feb 10 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Cancer, tumors, Prostate Cancer, Tumor, Prostate Cancer Foundation, Data, reserach and development, Seqencing
-
The studies were carried out and then halted upon finding out that one of the biostatisticians lied about his background. Much of the published information on the trials has now been retracted and now the FDA is looking into the situation to get additional information. Credentials and backgrounds...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Jan 28 2011
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Cancer, FDA, clinical trials, Duke University, Journals, credentials, Cancer letter, ID
-
Just a couple weeks ago, Amgen contracted with Boehringer Ingelheim to take over their Fremont, California location so all employees will now report to Boehringer Ingelheim, which has it headquarters in Germany. BioVex is working on a new approach to treating melanoma and head and neck cancer and...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Jan 25 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Biotech, Cancer, clinical trials, Amgen, Vaccine, Mergers and Acquisitions, stock, transactions, head cancer, melinoma, BioVex, biotechnology
-
Back in September of 2010 he was also names to the Board of another technology company that deals with urology and cancer therapies. Since his tenure at the FDA it sounds like von Eschenbach is returning to his roots with using his expertise in the clinical area of healthcare. BD Former FDA...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Jan 19 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Cancer, FDA, Prostate Cancer, Pharmaceuticals, National Cancer Institute, enzymes, Durham, Viamet Pharmaceuticals, drug discovery, Andrew von Eschenbach
-
Boehringer Ingelheim has been a contracted vendor for years for Amgen so the contracting just became a little larger today and employees now belong to Boehringer Ingelheim. Boehringer Ingelheim was also in the news last year with their FDA approval of Pradaxa, an alternative for blood thinning to Warfarin...
-
REMS programs are required by the FDA for certain marketed drugs to ensure the benefits of a product offered to consumers outweigh the risks . They can include elements to ensure safe use, communications plans and medication guides, which all require assessment. Just a few months ago, another REMS...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Mon, Jan 10 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Cancer, FDA, Pain Relief, REMS, risk evalaution and mitigation strategy, addictive drugs, ProStraken), Abstral, register
-
Dr. Daniel Haber, chief of Massachusetts General Hospital’s cancer center is the inventor of the blood test process and the hospital will be working with Johnson and Johnson companies Veridex, LLC, and Ortho Biotech Oncology R&D. There have been specific blood tests such as the one noted below...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Mon, Jan 3 2011
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Cancer, Johnson and Johnson, Research and Development, Stand up to Cancer, Massachusetts General Hospital, Veridex, Ortho Biotech Oncology
-
The acquisition contains a lot of technology solutions here, if not almost all technology solutions with those algorithms. I guess we are beginning to see this focused everywhere today with modeling physician performance adding additional compensation for the business models. In the text...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Thu, Dec 30 2010
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Health IT, McKesson, Cancer, Oncology, Doctors, Patients, Mergers and Acquisitions, US Oncology
-
I think they should have their day in court to submit their findings and substantiate the use of Avastin for breast cancer . This is not a new product and has been used to treat breast cancer and it has helped many women. Now what other data could the FDA have looking at? Did one of the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Dec 28 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, health insurance, Claims, Cancer, Oncology, Breast Cancer, Roche, United HealthCare, healthcare reform, Susan G. Komen, Avastic, FDA. Genentech
-
If you follow along this blog, then you may already know there are women and children walking around with bladders that have been grown in labs , amazing technology. Below is a link with a couple videos that explains the process and now we have a new revelation where bone marrow cells can be used...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Nov 26 2010
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Cancer, Science, kidney, Research and Development, Stem Cells, Transplants, Regenerative Medicine, Bone Marrow, Wake Forest, bladders
-
Here in the US, Genentech, known for their cancer drugs and research is expected to be hit as well, although no particular numbers are out. Last year Roche took over Genentech for $47 billion, huge purchase here, but the company always had maintained an invested interest. The company has...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Nov 17 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Biotech, Cancer, Oncology, Marketing, Genentech, Roche, Research and Development, Sales, Layoffs, RNAi